Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, with therapeutic and preventive approaches advancing in parallel.

The spread of human immunodeficiency virus 1 (HIV-1) infections increased despite restrictions on the border between Mexico and the United States during the COVID-19 pandemic, according to a ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Background People living with HIV (PWH) are at increased risk of cardiovascular disease; however, evidence from Asian populations remains limited. We evaluated the prevalence and characteristics of ...